BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33119152)

  • 1. Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Battipaglia G; Labopin M; Hamladji RM; Blaise D; Chevallier P; Brissot E; Gerbitz A; Socié G; Afanasyev B; Ciceri F; Meijer E; Koc Y; Cornelissen JJ; Huynh A; Ozdogu H; Maertens J; Paul F; Labussière-Wallet H; Ruggeri A; Aljurf M; Bazarbachi A; Savani B; Nagler A; Mohty M
    Cancer; 2021 Jan; 127(2):209-218. PubMed ID: 33119152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors.
    Brissot E; Labopin M; Moiseev I; Cornelissen JJ; Meijer E; Van Gorkom G; Rovira M; Ciceri F; Griskevicius L; Blaise D; Forcade E; Mistrik M; Mielke S; Bulabois CE; Niittyvuopio R; Deconinck E; Ruggeri A; Sanz J; Spyridonidis A; Savani B; Giebel S; Nagler A; Mohty M
    J Hematol Oncol; 2020 Jul; 13(1):87. PubMed ID: 32620146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of Antithymocyte Globulin-Post-Transplantation Cyclophosphamide-Cyclosporine-Based versus Antithymocyte Globulin-Based Prophylaxis for 10/10 HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation.
    Salas MQ; Alfaro-Moya T; Atenafu EG; Datt Law A; Lam W; Pasic I; Novitzky-Basso I; Santos Carreira A; Chen C; Michelis FV; Gerbitz A; Howard Lipton J; Kim DDH; Kumar R; Mattsson J; Viswabandya A
    Transplant Cell Ther; 2024 May; 30(5):536.e1-536.e13. PubMed ID: 38281592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual T-cell depletion with individually tailored anti-thymocyte globulin and attenuated dose of post-transplant cyclophosphamide in haploidentical peripheral stem cell transplantation.
    Kim DH; Shin DY; Koh Y; Kim I; Yoon SS; Byun JM; Hong J
    Sci Rep; 2024 Jun; 14(1):13885. PubMed ID: 38880835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparable outcomes of allogeneic peripheral blood versus bone marrow hematopoietic stem cell transplantation from a sibling donor for pediatric patients.
    Kim BK; Hong KT; Choi JY; Kim H; Park HJ; Kang HJ
    Ann Hematol; 2024 Jun; 103(6):2051-2058. PubMed ID: 38594416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus Reactivations in Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Matched and Haploidentical Donors with Post-Transplantation Cyclophosphamide.
    Chorão P; Henriques M; Villalba M; Montoro J; Balaguer-Roselló A; González EM; Gómez MD; Gómez I; Solves P; Santiago M; Asensi P; Lamas B; Bataller A; Granados P; Eiris J; Martínez D; Louro A; Rebollar P; Perla A; Salavert M; de la Rubia J; Sanz MÁ; Sanz J
    Transplant Cell Ther; 2024 May; 30(5):538.e1-538.e10. PubMed ID: 38331195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-transplant сyclophosphamide after matched donor hematopoietic stem cell transplantation in children with acute leukemia.
    Borovkova AS; Paina OV; Semenova EV; Bykova TA; Osipova AA; Slesarchuk OA; Kozhokar PV; Tsvetkova LA; Rakhmanova ZZ; Kozlov AV; Chukhlovin AB; Kazantsev IV; Estrina MA; Goloshchapov OV; Bondarenko SN; Moiseev IS; Kulagin AD; Zubarovskaya LS
    Clin Transplant; 2024 Jan; 38(1):e15181. PubMed ID: 37922213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?
    Penack O; Abouqateb M; Peczynski C; Boreland W; Kröger N; Stelljes M; Gedde-Dahl T; Blau IW; Schroeder T; Salmenniemi U; Kulagin A; Peffault de Latour R; Mielke S; Zeiser R; Moiseev I; Schoemans H; Koenecke C; Peric Z
    Leukemia; 2024 May; 38(5):1156-1163. PubMed ID: 38538862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloablative Haploidentical Donor Hematopoietic Transplantation Using Post-Transplantation Cyclophosphamide and Antithymocyte Globulin.
    El Fakih R; Nassani M; Rasheed W; Hanbali A; Almohareb F; Chaudhri N; Alsharif F; Alfraih F; Shaheen M; Alhayli S; Alkhaldi H; Alshaibani A; Alotaibi AS; Alahmari A; Alamer A; Tarig A; Youniss R; Albabtain AA; Alfayez M; Saad A; Ahmed SO; Alzahrani H; Aljurf M
    Transplant Cell Ther; 2024 Mar; 30(3):312.e1-312.e7. PubMed ID: 38185379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graft Failure Incidence, Risk Factors, and Outcomes in Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.
    Mata JR; Zahurak M; Rosen N; DeZern AE; Jones RJ; Ambinder AJ
    Transplant Cell Ther; 2024 Jun; 30(6):588-596. PubMed ID: 38521411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.
    Brissot E; Labopin M; Stelljes M; Ehninger G; Schwerdtfeger R; Finke J; Kolb HJ; Ganser A; Schäfer-Eckart K; Zander AR; Bunjes D; Mielke S; Bethge WA; Milpied N; Kalhs P; Blau IW; Kröger N; Vitek A; Gramatzki M; Holler E; Schmid C; Esteve J; Mohty M; Nagler A
    J Hematol Oncol; 2017 Jun; 10(1):130. PubMed ID: 28646908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Swoboda R; Schroeder T; Hamladji RM; Griskevicius L; Salmenniemi U; Rambaldi A; Mielke S; Kulagin A; Passweg J; Luft T; Gedde-Dahl T; Forcade E; Helbig G; Stelljes M; Castilla-Llorente C; Spyridonidis A; Brissot E; Ciceri F; Mohty M
    Bone Marrow Transplant; 2024 Apr; ():. PubMed ID: 38615143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft-versus-host-disease prophylaxis with ATG or PTCY in patients with lymphoproliferative disorders undergoing reduced intensity conditioning regimen HCT from one antigen mismatched unrelated donor.
    Paviglianiti A; Ngoya M; Peña M; Boumendil A; Gülbas Z; Ciceri F; Bonifazi F; Russo D; Fegueux N; Stolzel F; Bulabois CE; Socié G; Forcade E; Solano C; Finel H; Robinson S; Glass B; Montoto S
    Bone Marrow Transplant; 2024 May; 59(5):597-603. PubMed ID: 38331980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party.
    Bazarbachi AH; Labopin M; Raiola AM; Blaise D; Arcese W; Santarone S; Koc Y; Bramanti S; Kulagin A; Kwon M; Sica S; Sanz J; Brissot E; Nagler A; Ciceri F; Mohty M
    Cancer; 2024 May; ():. PubMed ID: 38758817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation.
    Penack O; Abouqateb M; Peczynski C; Boreland W; Gülbas Z; Gedde-Dahl T; Castilla-Llorente C; Kröger N; Eder M; Rambaldi A; Bonifazi F; Blau IW; Stelljes M; Dreger P; Moiseev I; Schoemans H; Koenecke C; Peric Z
    Blood Cancer J; 2024 Mar; 14(1):45. PubMed ID: 38485723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Ngoya M; Galimard JE; Labopin M; Blau IW; Kröger N; Gedde-Dahl T; Schroeder T; Burns D; Salmenniemi U; Rambaldi A; Choi G; Peffault de Latour R; Vydra J; Sengeloev H; Eder M; Mielke S; Forcade E; Kulagin A; Ciceri F; Mohty M
    Am J Hematol; 2024 Jun; ():. PubMed ID: 38856236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and Impact of Fungal Infections in Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis and Haploidentical Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
    Papanicolaou GA; Chen M; He N; Martens MJ; Kim S; Batista MV; Bhatt NS; Hematti P; Hill JA; Liu H; Nathan S; Seftel MD; Sharma A; Waller EK; Wingard JR; Young JH; Dandoy CE; Perales MA; Chemaly RF; Riches M; Ustun C
    Transplant Cell Ther; 2024 Jan; 30(1):114.e1-114.e16. PubMed ID: 37775070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia.
    Holter-Chakrabarty JL; Pierson N; Zhang MJ; Zhu X; Akpek G; Aljurf MD; Artz AS; Baron F; Bredeson CN; Dvorak CC; Epstein RB; Lazarus HM; Olsson RF; Selby GB; Williams KM; Cooke KR; Pasquini MC; McCarthy PL
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1251-7. PubMed ID: 25840335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.
    Kanakry CG; Tsai HL; Bolaños-Meade J; Smith BD; Gojo I; Kanakry JA; Kasamon YL; Gladstone DE; Matsui W; Borrello I; Huff CA; Swinnen LJ; Powell JD; Pratz KW; DeZern AE; Showel MM; McDevitt MA; Brodsky RA; Levis MJ; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
    Blood; 2014 Dec; 124(25):3817-27. PubMed ID: 25316679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia.
    Hahn T; McCarthy PL; Zhang MJ; Wang D; Arora M; Frangoul H; Gale RP; Hale GA; Horan J; Isola L; Maziarz RT; van Rood JJ; Gupta V; Halter J; Reddy V; Tiberghien P; Litzow M; Anasetti C; Pavletic S; Ringdén O
    J Clin Oncol; 2008 Dec; 26(35):5728-34. PubMed ID: 18981462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.